You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TP53/Rb1

Showing 1 - 25 of 2,213
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Trial in United States (Osimertinib, Platinum, Etoposide)

Recruiting
  • Lung Cancer
  • Basking Ridge, New Jersey
  • +6 more
Jul 1, 2022

Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +6 more
  • TP53-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

Not yet recruiting
  • Aumolertinib
  • +4 more
  • (no location specified)
Mar 8, 2023

Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer Trial in Toronto (RP-6306, Carboplatin, Paclitaxel)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Oct 25, 2023

NSCLC, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma Trial in Duarte (Autologous, engineered T Cells targeting

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +5 more
  • Autologous, engineered T Cells targeting TP53 R175H
  • Duarte, California
    City of Hope
May 17, 2023

Tumors, Ovarian Cancer, Breast Cancer Trial in Houston (ZN-c3, Bevacizumab, Pembrolizumab)

Not yet recruiting
  • Tumors
  • +4 more
  • Houston, Texas
    MD Anderson Cancer Center
Jun 20, 2022

MDS, MDS Trial in Tampa, Boston, Houston (APR-548 + Azacitidine)

Terminated
  • MDS
  • Myelodysplastic Syndromes
  • APR-548 + Azacitidine
  • Tampa, Florida
  • +3 more
Jul 20, 2022

p53 and Response to Preoperative Radiotherapy for T2 and T3

Recruiting
  • Rectal Cancer
  • preoperative short course radiation
  • Vienna, Austria
    Medical University of Vienna, Department of Surgery
Apr 6, 2022

Prevention of Chemo-induced Myelosuppression Trial in Worldwide (ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500

Recruiting
  • Prevention of Chemotherapy-induced Myelosuppression
  • ALRN-6924
  • TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
  • Tamarac, Florida
  • +14 more
Jan 31, 2023

Solid Tumor Trial in United States (ASTX295)

Recruiting
  • Solid Tumor
  • Duarte, California
  • +9 more
Nov 18, 2022

Patogenic Mutation in 5 Genes

Completed
  • Colorectal Cancer
  • +5 more
  • co-occuring mutation
  • Jakarta, ALL, Indonesia
    Vania Myralda Giamour Marbun
Jul 21, 2021

Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Tumor Trial in United States (APR-246, Azacitidine)

Completed
Has Results
  • Myelodysplastic Syndrome
  • +3 more
  • Tampa, Florida
  • +5 more
Jan 14, 2022

Hematologic Malignancy, Acute Leukemia, Remission Trial (Fludarabine, Busulfan, Melphalan)

Not yet recruiting
  • Hematologic Malignancy
  • +21 more
  • (no location specified)
Feb 9, 2023

Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage

Active, not recruiting
  • Clinical Stage III Gastric Cancer AJCC v8
  • +7 more
  • Duarte, California
  • +30 more
Jan 7, 2023

Large-Cell Neuroendocrine Carcinoma Trial in Lexington (Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma,

Recruiting
  • Large-Cell Neuroendocrine Carcinoma
  • Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma
  • Treatment for Small Cell Lung Cancer
  • Lexington, Kentucky
    Markey Cancer Center, University of Kentucky
Jan 12, 2022

Chronic Lymphocytic Leukemia (CLL) Trial in Worldwide (Obinutuzumab, Venetoclax, Fludarabine)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Aurora, Colorado
  • +55 more
Jan 30, 2023

Chronic Lymphocytic Leukemia Trial in Worldwide (Venetoclax)

Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • Louisville, Kentucky
  • +66 more
Nov 9, 2022

Myeloid Leukemia, MDS Trial (IFN-?)

Not yet recruiting
  • Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Nov 15, 2023

Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome Trial in Boston (Data and Specimen Collection)

Recruiting
  • Li-Fraumeni Syndrome
  • +4 more
  • Data and Specimen Collection
  • Boston, Massachusetts
  • +2 more
Jan 23, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Shanghai, Shanhai, China
    Ruijin Hospital
Sep 29, 2023

Non Small Cell Lung Cancer Trial in Italy (Osimertinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Ancona, Italy
  • +10 more
Mar 14, 2023

Lymphoma, Mantle-Cell Trial in Shanghai (Zanubrutinib, Rituximab, Bendamustin)

Not yet recruiting
  • Lymphoma, Mantle-Cell
  • Shanghai, Shanghai, China
    Ruijin Hospital
Nov 14, 2023

NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)

Not yet recruiting
  • NSCLC
  • Non-small Cell Lung Cancer
  • Apatinib + Fluzoparib
  • Apatinib + Fluzoparib + Adebrelimab
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 27, 2023

Patients With Breast Cancer and Pathogenic Variants of TP53

Completed
  • Breast Cancer
  • +3 more
  • No intervention in this study
  • São Paulo, Brazil
    ICESP
Aug 5, 2022

Leukemia, Lymphocytic, Chronic Trial in Germany (ibrutinib, obinutuzumab, venetoclax)

Completed
  • Leukemia, Lymphocytic, Chronic
  • Dresden, Germany
  • +10 more
Jan 13, 2023